Regeneron in United States — Pulmonology: the full competitive set, and the 1 AXLRx report covering them with market-access, payer and competitive detail, every figure verified to a live source.
Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier.
We use analytics cookies to see how visitors use AXLRx. They're only set if you accept — decline and none are placed. See our Privacy Policy.